Last reviewed · How we verify
Kawasaki's disease
Approved treatments
- Sandimmune · Novartis
- Sandimmune · Novartis AG (originally Sandoz)
Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection. - ciclosporine · Hospices Civils de Lyon
- Neoral · Novartis Pharmaceuticals
- Cyclosporin · Karolinska University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Kawasaki's disease patent landscape — cliff calendar, originator estates, attackable patents
- Kawasaki's disease treatment landscape brief
- Kawasaki's disease treatment updates RSS
Frequently asked questions about Kawasaki's disease
What drugs treat Kawasaki's disease?
Tracked treatments include Sandimmune, ciclosporine, Neoral, Cyclosporin.
What is the treatment for Kawasaki's disease?
Standard treatment for Kawasaki's disease includes Sandimmune, ciclosporine, Neoral, Cyclosporin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Kawasaki's disease patent cliff · Kawasaki's disease CI report
- Treatment: Sandimmune · Novartis
- Treatment: Sandimmune · Novartis AG (originally Sandoz)
- Treatment: ciclosporine · Hospices Civils de Lyon
- Treatment: Neoral · Novartis Pharmaceuticals
- Treatment: Cyclosporin · Karolinska University Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing